Bio-Techne (TECH) Scheduled to Post Earnings on Wednesday

Bio-Techne (NASDAQ:TECH - Get Free Report) will announce its earnings results before the market opens on Wednesday, October 30th. Analysts expect the company to announce earnings of $0.34 per share for the quarter. Investors that are interested in participating in the company's conference call can do so using this link.

Bio-Techne (NASDAQ:TECH - Get Free Report) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported $0.49 EPS for the quarter, hitting analysts' consensus estimates of $0.49. Bio-Techne had a return on equity of 12.88% and a net margin of 14.50%. The firm had revenue of $306.10 million for the quarter, compared to the consensus estimate of $306.49 million. During the same quarter in the prior year, the business earned $0.56 earnings per share. The company's revenue was up 1.6% compared to the same quarter last year. On average, analysts expect Bio-Techne to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bio-Techne Stock Performance

NASDAQ:TECH traded down $0.61 during trading hours on Wednesday, reaching $69.34. The company had a trading volume of 734,622 shares, compared to its average volume of 1,012,410. The firm has a market cap of $11.00 billion, a PE ratio of 66.67, a price-to-earnings-growth ratio of 5.15 and a beta of 1.27. Bio-Techne has a 1-year low of $51.79 and a 1-year high of $85.57. The business's 50 day moving average price is $73.95 and its 200-day moving average price is $74.47. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.87 and a quick ratio of 2.75.

Bio-Techne Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 30th. Stockholders of record on Monday, August 19th were paid a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a dividend yield of 0.46%. The ex-dividend date of this dividend was Monday, August 19th. Bio-Techne's payout ratio is currently 30.77%.

Analyst Ratings Changes

Several analysts have commented on the company. Robert W. Baird raised their price objective on Bio-Techne from $81.00 to $82.00 and gave the company an "outperform" rating in a report on Thursday, August 8th. Benchmark reiterated a "buy" rating and set a $95.00 target price on shares of Bio-Techne in a research report on Tuesday, August 13th. Finally, Royal Bank of Canada cut their price target on shares of Bio-Techne from $72.00 to $70.00 and set a "sector perform" rating for the company in a report on Thursday, August 8th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Bio-Techne currently has a consensus rating of "Moderate Buy" and an average target price of $80.60.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.